Funding round completed
Agendia NV, a specialist in molecular cancer diagnostics, has announced the closing of a €16.6 million fifth round of private investment. The money, from an international syndicate of both new and existing investors, and is the largest private placement in the Benelux healthcare technology sector in the year to date.
Agendia, a spin-out from the Netherlands Cancer Institute, uses tumour gene expression profiles as the basis of diagnostic tests and was the first company to commercialise a prognostic test – MammaPrint, which predicts the risk of breast cancer recurrence.
The company said success of this financing round was underpinned by increasing US demand for MammaPrint, and growing reimbursement from private US health payers. The proceeds will be used to accelerate the commercialisation of MammaPrint in the US market.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.